Anti-Estrogen Raloxifene HCl SERMs Raloxifene Hydrochloride Em pó
Raloxifene Hydrochloride/Raloxifene HCL Specification:
| Raloxifene Hydrochloride Name | Cloridrato de raloxifene |
| Raloxifene Hydrochloride Alias | Raloxifene HCl |
| Raloxifene Hydrochloride CAS | 82640-04-8 |
| Ensaio de cloridrato de raloxifeno | 99% |
| Raloxifene Hydrochloride Molecular Formula | C28H28ClNO4S |
| Raloxifene Hydrochloride Molecular weight | 510.05 |
| Raloxifene Hydrochloride Appearance | pó cristalino branco |
| Raloxifene Hydrochloride Grade | Qualidade farmacêutica |
Raloxifene Hydrochloride/Raloxifene HCL Descrição
Raloxifene Hcl is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene hydrochloride acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. Raloxifene Hcl have efficacy against estrogen-sensitive cancers.
Raloxifene Hcl is an estrogen agonist antagonist, referred to as a selective estrogen receptor modulator and belongs to the benzothiophene class of compounds. The Raloxifene Hcl biological actions are largely mediated through binding to estrogen receptors, and it binding results in activation of estrogenic pathways in some tissues Agonism and and the blockade of estrogenic pathways in Antagonism.
Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Raloxifene hydrochloride is approved to prevent Breast cancer. It is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis.
Raloxifene Hydrochloride/Hydrochloride HCL Usidade in Cancer
1) Raloxifene Hcl used to prevent & treat osteoporosis in women who have undergone menopause.
2) Raloxifene Hcl used to decrease the risk of developing invasive breast cancer in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene Hcl cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
3) Raloxifene Hcl prevents and treats osteoporosis by mimicking the effects of estrogen to increase the density (thickness) of bone.
4) Raloxifene Hcl decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue, which may stop the development of tumors that need estrogen to grow.
Raloxifene Hydrochloride/Raloxifene HCL Dosagem:
Raloxifene Hcl recommended initial dose is one 60 mg tablet daily. It may administered any time of day without regard to meals.
The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1-2 hours after breakfast. Bodybuilder dosage recommendations are consistent with those of patients, and should be individualized to obtain an adequate response with the lowest effective dose.
For some patients or bodybuilders half a tablet (18.75 mg) daily may be adequate, while others might take half a dose twice daily.
